Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
6 min read
Tulisokibart Biologics Sequence Review Report 2026: TL1A Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tulisokibart, an antibody targeting TL1A.
Read →
Latest Hotspot
6 min read
Suvemcitug Biologics Sequence Review Report 2026: VEGF-A Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Suvemcitug, an antibody targeting VEGF-A.
Read →
Latest Hotspot
6 min read
Riliprubart Biologics Sequence Review Report 2026: C1s Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Riliprubart, an antibody targeting C1s.
Read →
Latest Hotspot
6 min read
Rademikibart Biologics Sequence Review Report 2026: IL-4Ralpha Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rademikibart, an antibody targeting IL-4Ralpha.
Read →
Latest Hotspot
6 min read
Nisevokitug Biologics Sequence Review Report 2026: TGF-beta1 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nisevokitug, an antibody targeting TGF-beta1.
Read →
Latest Hotspot
6 min read
Mevonlerbart Biologics Sequence Review Report 2026: Fel d 1 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mevonlerbart, an antibody targeting Fel d 1.
Read →
Latest Hotspot
6 min read
Gotistobart Biologics Sequence Review Report 2026: CTLA-4 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gotistobart, an antibody targeting CTLA-4.
Read →
Latest Hotspot
6 min read
Freneslerbart Biologics Sequence Review Report 2026: Fel d 1 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Freneslerbart, an antibody targeting Fel d 1.
Read →
Latest Hotspot
6 min read
Ersodetug Biologics Sequence Review Report 2026: Insulin receptor Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ersodetug, an antibody targeting Insulin receptor.
Read →
Latest Hotspot
6 min read
Empasiprubart Biologics Sequence Review Report 2026: C2 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Empasiprubart, an antibody targeting C2.
Read →
Latest Hotspot
6 min read
Denecimig Biologics Sequence Review Report 2026: Factor IX × Factor X Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Denecimig, an antibody targeting Factor IX × Factor X.
Read →
Latest Hotspot
6 min read
Delpacibart Biologics Sequence Review Report 2026: CD71 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Delpacibart, an antibody targeting CD71.
Read →
<
1
<<
119
120
121
122
123
>>
979
>